Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Financial Select Sector SPDR Fund (XLF) Price & Performance

Inovio Pharmaceuticals IncTrade
Financial Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Financial Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $0.79 (market cap $78.55M), while Financial Select Sector SPDR Fund trades at $58.06. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INOXLF
Market Cap
$78.55M
Sector
Health
52-Week High
$2.87$58.01
52-Week Low
$0.66$47.80
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Financial Select Sector SPDR Fund

XLF, the Financial Select Sector SPDR ETF, trades at $57.91, up 0.17% today, with a bullish technical signal driven by moving averages. Recent news highlights record inflows into sector ETFs and strong Q2 bank earnings, while technical indicators show overbought RSI levels. The ETF crossed above its 200-day moving average, signaling positive momentum.

The outlook for XLF is positive due to sector strength and AI-driven financial opportunities, but risks include market volatility and high expectations. Investors benefit from diversification and a dividend yield, though overbought conditions suggest potential near-term consolidation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Financial Select Sector SPDR Fund

The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.

Read more on XLF